CN107683134B - 多西他赛及人血清白蛋白复合物 - Google Patents

多西他赛及人血清白蛋白复合物 Download PDF

Info

Publication number
CN107683134B
CN107683134B CN201680021595.6A CN201680021595A CN107683134B CN 107683134 B CN107683134 B CN 107683134B CN 201680021595 A CN201680021595 A CN 201680021595A CN 107683134 B CN107683134 B CN 107683134B
Authority
CN
China
Prior art keywords
docetaxel
serum albumin
human serum
aqueous solution
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680021595.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN107683134A (zh
Inventor
孙群
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhuhai Beihai Biotech Co Ltd
Original Assignee
Zhuhai Beihai Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhuhai Beihai Biotech Co Ltd filed Critical Zhuhai Beihai Biotech Co Ltd
Priority to CN202110271253.2A priority Critical patent/CN112807299B/zh
Publication of CN107683134A publication Critical patent/CN107683134A/zh
Application granted granted Critical
Publication of CN107683134B publication Critical patent/CN107683134B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201680021595.6A 2015-05-15 2016-05-16 多西他赛及人血清白蛋白复合物 Active CN107683134B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110271253.2A CN112807299B (zh) 2015-05-15 2016-05-16 包含多西他赛和人血清白蛋白的固体组合物及其制备方法和应用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562162545P 2015-05-15 2015-05-15
US62/162,545 2015-05-15
US201562209053P 2015-08-24 2015-08-24
US62/209,053 2015-08-24
US201662299209P 2016-02-24 2016-02-24
US62/299,209 2016-02-24
PCT/US2016/032760 WO2016187147A1 (en) 2015-05-15 2016-05-16 Docetaxel and human serum albumin complexes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110271253.2A Division CN112807299B (zh) 2015-05-15 2016-05-16 包含多西他赛和人血清白蛋白的固体组合物及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN107683134A CN107683134A (zh) 2018-02-09
CN107683134B true CN107683134B (zh) 2021-02-23

Family

ID=57320749

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680021595.6A Active CN107683134B (zh) 2015-05-15 2016-05-16 多西他赛及人血清白蛋白复合物
CN202110271253.2A Active CN112807299B (zh) 2015-05-15 2016-05-16 包含多西他赛和人血清白蛋白的固体组合物及其制备方法和应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110271253.2A Active CN112807299B (zh) 2015-05-15 2016-05-16 包含多西他赛和人血清白蛋白的固体组合物及其制备方法和应用

Country Status (5)

Country Link
US (2) US10500285B2 (enExample)
EP (1) EP3294286A4 (enExample)
JP (1) JP2018527287A (enExample)
CN (2) CN107683134B (enExample)
WO (1) WO2016187147A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10500285B2 (en) * 2015-05-15 2019-12-10 Zhuhai Beihai Biotech Co., Ltd. Docetaxel and human serum albumin complexes
WO2018035406A1 (en) * 2016-08-19 2018-02-22 Zhuhai Beihai Biotech Co., Ltd. Formulations of ibrutinib
US11419842B2 (en) 2016-10-27 2022-08-23 Zhuhai Beihai Biotech Co., Ltd. Neutral pH compositions of Docetaxel and human serum albumin
US20200061020A1 (en) * 2017-05-01 2020-02-27 Zhuhai Beihai Biotech Co., Ltd. Formulations and compositions of docetaxel
CN116747217B (zh) * 2018-04-11 2024-04-26 珠海贝海生物技术有限公司 多西他赛制剂和组合物
EP3866834A1 (en) 2018-10-17 2021-08-25 Sunstate Biosciences, LLC Single protein-encapsulated pharmaceutics for enhancing therapeutic effects
CN115297857B (zh) * 2020-02-04 2024-07-19 珠海贝海生物技术有限公司 多西他赛制剂
CN115400115B (zh) * 2021-05-26 2025-01-14 石药集团中奇制药技术（石家庄）有限公司 多西他赛白蛋白组合物和免疫检查点抑制剂的组合及用途
CN113577267B (zh) * 2021-09-06 2022-04-08 江西北正干细胞生物科技有限公司 Nk细胞和抗体的药物组合物及其在治疗癌症中的用途
CA3252932A1 (en) * 2022-02-25 2025-03-03 Zhuhai Beihai Biotech Co., Ltd. Docetaxel compositions and methods
WO2024230772A1 (zh) * 2023-05-09 2024-11-14 江苏康宁杰瑞生物制药有限公司 包含抗her2双特异性抗体的联合治疗药物及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050282734A1 (en) * 1998-07-30 2005-12-22 Kadima Tenshuk A Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
CN101361731A (zh) * 2008-08-11 2009-02-11 张文芳 白蛋白稳定的多西紫杉醇冻干制剂及其在治疗肿瘤方面的应用
US20110190204A1 (en) * 2010-02-03 2011-08-04 Oncbiomune, L.L.C. Taxane- and Taxoid-Protein Compositions
US20140017323A1 (en) * 2010-03-29 2014-01-16 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
WO2014121033A1 (en) * 2013-02-04 2014-08-07 Fl Therapeutics Llc Soluble complexes of drug analogs and albumin

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58216126A (ja) * 1982-06-11 1983-12-15 Ono Pharmaceut Co Ltd 可容化製剤
EP0932399B1 (en) * 1996-03-12 2006-01-04 PG-TXL Company, L.P. Water soluble paclitaxel prodrugs
HUP9701554D0 (en) 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
CA2620308A1 (en) 2005-10-12 2007-04-19 Sicor Inc. Crystalline forms of docetaxel and processes for their preparation
KR20080100264A (ko) 2006-03-21 2008-11-14 닥터 레디스 레보러터리즈 리미티드 도세탁셀의 다형체와 그 제조방법
CA2756603C (en) 2006-10-20 2013-05-28 Scinopharm Singapore Pte, Ltd. Process for making crystalline docetaxel trihydrate
WO2008102374A1 (en) 2007-02-20 2008-08-28 Dabur Pharma Limited Amorphous form of docetaxel
KR100878455B1 (ko) 2007-04-10 2009-01-13 한미약품 주식회사 안정한 무수결정형 도세탁셀 및 이의 제조방법
US20100197944A1 (en) 2007-07-04 2010-08-05 Dr. Reddy's Laboratories Limited Docetaxel process and polymorphs
CN101357126A (zh) * 2008-08-11 2009-02-04 张文芳 一种稳定的紫杉烷类白蛋白脂质载药系统及其制备方法
CN101658516B (zh) * 2008-08-26 2011-10-05 齐鲁制药有限公司 紫杉醇类药物组合物及其制备方法
CZ303072B6 (cs) 2009-02-13 2012-03-21 Zentiva, K.S. Polymerní konjugáty paclitaxelu a docetaxelu s pH rízeným uvolnováním kancerostatika
KR101149600B1 (ko) 2009-12-31 2012-05-29 주식회사 삼양제넥스바이오 고순도 무수결정형 도세탁셀 제조방법
US8890233B2 (en) 2010-07-06 2014-11-18 Macronix International Co., Ltd. 3D memory array with improved SSL and BL contact layout
CN101926757B (zh) * 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
KR20120096200A (ko) 2011-02-22 2012-08-30 동아제약주식회사 결정형 도세탁셀 및 이의 제조방법
CN102688200B (zh) * 2012-05-09 2014-03-26 广州帝奇医药技术有限公司 植物类抗癌靶向纳米制剂及其制备方法
US10500285B2 (en) * 2015-05-15 2019-12-10 Zhuhai Beihai Biotech Co., Ltd. Docetaxel and human serum albumin complexes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050282734A1 (en) * 1998-07-30 2005-12-22 Kadima Tenshuk A Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
CN101361731A (zh) * 2008-08-11 2009-02-11 张文芳 白蛋白稳定的多西紫杉醇冻干制剂及其在治疗肿瘤方面的应用
US20110190204A1 (en) * 2010-02-03 2011-08-04 Oncbiomune, L.L.C. Taxane- and Taxoid-Protein Compositions
US20140017323A1 (en) * 2010-03-29 2014-01-16 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
WO2014121033A1 (en) * 2013-02-04 2014-08-07 Fl Therapeutics Llc Soluble complexes of drug analogs and albumin

Also Published As

Publication number Publication date
US20180289818A1 (en) 2018-10-11
EP3294286A1 (en) 2018-03-21
CN112807299A (zh) 2021-05-18
JP2018527287A (ja) 2018-09-20
US10500285B2 (en) 2019-12-10
US10780172B2 (en) 2020-09-22
US20200061194A1 (en) 2020-02-27
WO2016187147A1 (en) 2016-11-24
CN112807299B (zh) 2022-06-24
EP3294286A4 (en) 2019-01-02
CN107683134A (zh) 2018-02-09

Similar Documents

Publication Publication Date Title
CN107683134B (zh) 多西他赛及人血清白蛋白复合物
US11510895B2 (en) Compositions and formulations including cabazitaxel and human serum albumin
US12128022B2 (en) Neutral pH compositions of docetaxel and human serum albumin
CN109922790B (zh) 卡博替尼制剂
CN112055588B (zh) 卡巴他赛的制剂和组合物
US20240189272A1 (en) Formulations and compositions of docetaxel
WO2019200084A1 (en) Formulations and compositions of docetaxel
CN109715213B (zh) 依鲁替尼制剂
HK40085284A (en) Neutral ph compositions of docetaxel and human serum albumin
HK40085284B (zh) 多西他赛和人血清白蛋白的中性ph组合物
HK40086850A (zh) 包含卡巴他赛和人血清白蛋白的组合物和制剂
HK40086850B (zh) 包含卡巴他赛和人血清白蛋白的组合物和制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP02 Change in the address of a patent holder
CP02 Change in the address of a patent holder

Address after: 519090 zone a, floor 3, plant 2, No. 6366, Zhuhai Avenue, Jinwan District, Zhuhai City, Guangdong Province

Patentee after: ZHUHAI BEIHAI BIOTECH CO.,LTD.

Address before: Unit A6, 4th floor, No.10, Keji 1st Road, Gangwan Avenue, Tangjiawan Town, Zhuhai City, Guangdong Province, 519000

Patentee before: ZHUHAI BEIHAI BIOTECH CO.,LTD.